KRAS and non-small cell lung carcinoma: Based on the positive results from the preliminary clinical trials, FDA has granted Sotorasib (AMG510) the title of breakthrough therapy for the treatment of locally advanced or metastatic NSCLC with KRAS G12C mutation on December 8, 2020.